{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:32:34Z","timestamp":1772166754003,"version":"3.50.1"},"reference-count":13,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death and necrosis. Antiangiogenesis agents such as bevacizumab, a humanized antivascular endothelial growth factor monoclonal antibody, might prevent revascularization during and after treatment with a vascular disrupting agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to bevacizumab (15 mg\/kg intravenously once every 3 weeks) or the combination of bevacizumab (15 mg\/kg) plus fosbretabulin (60 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) intravenously once every 3 weeks until disease progression or toxicity. Randomization was stratified by disease status (measurable v nonmeasurable), prior bevacizumab, and platinum-free interval. The primary end point was progression-free survival (PFS). The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study enrolled 107 patients. Median PFS was 4.8 months for bevacizumab and 7.3 months for bevacizumab plus fosbretabulin (hazard ratio, 0.69; 90% two-sided CI, 0.47 to 1.00; one-sided P = .05). The proportion responding (overall response rate) to bevacizumab was 28.2% among 39 patients with measurable disease and 35.7% among 42 patients treated with the combination. The relative probability of responding was 1.27 (90% CI, 0.74 to 2.17; one-sided P = .24). Adverse events greater than grade 3 were more common in the combination regimen than in bevacizumab only for hypertension (35% v 20%). There was one grade 3 thromboembolic event in the combination arm and one intestinal fistula in the bevacizumab only arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>On the basis of the PFS, overall response rate, and tolerability of these two antivascular therapies, further evaluation is warranted for this chemotherapy-free regimen. Fosbretabulin in combination with bevacizumab increases the risk of hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2015.65.8153","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:58:47Z","timestamp":1464051527000},"page":"2279-2286","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":61,"title":["Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study"],"prefix":"10.1200","volume":"34","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Darus","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Sutton","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai","family":"Balkissoon","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph\u2019s Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.11.029"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5345"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.759557"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040177"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2012.09.017"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2014.1949"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3376"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131321"},{"key":"B14","doi-asserted-by":"crossref","unstructured":"Jennison C, Turnbull BW: Group Sequential Methods With Applications to Clinical Trials. Boca Raton, FL, Chapman & Hall\/CRC, 2000, pp 49","DOI":"10.1201\/9781584888581"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70391-2"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2015.65.8153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:40:37Z","timestamp":1653806437000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2015.65.8153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":13,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016,7,1]]}},"alternative-id":["10.1200\/JCO.2015.65.8153"],"URL":"https:\/\/doi.org\/10.1200\/jco.2015.65.8153","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726377012.793527326","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]},"assertion":[{"value":"2016-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}